PALLAS: PALbociclib CoLlaborative adjuvant study: A randomized phase 3 trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone HR1/HER2-early breast cancer

被引：0

作者：

Mayer, E. L. ^{[1
]}

Demichele, A. M. ^{[2
]}

Pfeiler, G. ^{[3
]}

Barry, W. ^{[4
]}

Metzger, O. ^{[5
]}

Rastogi, P. ^{[6
]}

Symmans, F. ^{[7
]}

Burstein, H. J. ^{[4
]}

Miller, K. ^{[8
]}

Loibl, S. ^{[9
]}

Schmatloch, S. ^{[10
]}

Goulioti, T. ^{[11
]}

Zardavas, D. ^{[11
]}

Fesl, C. ^{[12
]}

Koehler, M. ^{[13
]}

Bartlett, C. Huang ^{[13
]}

Huang, X. ^{[14
]}

Piccart, M. ^{[15
]}

Winer, E. ^{[4
]}

Gnant, M. ^{[16
,17
]}

机构：

[1] Harvard Med Sch, Dana Farber Canc Inst, Breast Oncol Ctr, Boston, MA USA

[2] Univ Penn, Perelman Ctr Adv Med, Philadelphia, PA 19104 USA

[3] Med Univ Vienna, Gyneol & Obstet, Vienna, Austria

[4] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA

[5] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA

[6] Univ Pittsburgh Sch Hlth Sci, Div Hematol Oncol, Pittsburgh, PA USA

[7] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA

[8] Indiana Univ Sch Med, Hematol Oncol, Indianapolis, IN 46202 USA

[9] German Breast Grp GBG Forsch GmbH, Med & Res, Neu Isenburg, Germany

[10] Elisabeth Hosp, Senol, Kassel, Germany

[11] Breast Int Grp, Brussels, Belgium

[12] Austrian Breast & Colorectal Canc Study Grp ABCSG, Stat, Vienna, Austria

[13] Pfizer, Oncol, New York, NY USA

[14] Pfizer, Oncol, San Diego, CA USA

[15] Inst Jules Bordet, Chemotherapy Dept, Brussels, Belgium

[16] Med Univ Vienna, Dept Surg, Vienna, Austria

[17] Med Univ Vienna, Comprehens Canc Ctr, Vienna, Austria

来源：

ANNALS OF ONCOLOGY | 2017年 / 28卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

215TiP

引用

页数：1

共 50 条

[1] PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase 3 trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for HR+/HER2-early breast cancer
Mayer, Erica
DeMichele, Angela
Gnant, Michael
Barry, William
Pfeiler, Georg
Metzger, Otto
Burstein, Harold
Miller, Kathy
Rastogi, Priya
Loibl, Sibylle
Goulioti, Theodora
Zardavas, Dimitrios
Fesl, Christian
Koehler, Maria
Huang-Bartlett, Cynthia
Huang, Xin
Piccart, Martine
Winer, Eric
Wolff, Antonio
CANCER RESEARCH, 2018, 78 (04)
[2] PALLAS: PAlbociclib Collaborative Adjuvant Study: A randomized phase 3 trial of palbociclib with adjuvant endocrine therapy versus endocrine therapy alone for HR+/HER2-early breast cancer
Mayer, E.
DeMichele, A.
Dubsky, P.
Barry, W.
Metzger, O.
Symmans, W. F.
Burstein, H.
Miller, K.
Wolff, A.
Rastogi, P.
Loibl, S.
von Minckwitz, G.
Goulioti, T.
Zardavas, D.
Fesl, C.
Koehler, M.
Bartlett, C. Huang
Chen, L.
Piccart, M.
Winer, E.
Gnant, M.
CANCER RESEARCH, 2016, 76
[3] PALLAS: A randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2-early breast cancer
Mayer, E. L.
Gnant, M. I.
DeMichele, A.
Martin, M.
Burstein, H.
Prat, A.
Rubovszky, G.
Miller, K. D.
Pfeiler, G.
Winer, E. P.
Zdenkowski, N.
Anderson, D.
Nowecki, Z.
Loibl, S.
Fohler, H.
Metzger, O.
Fumagalli, D.
Theall, K. Puyana
Fesl, C.
Dueck, A.
ANNALS OF ONCOLOGY, 2020, 31 : S1145 - S1145
[4] Treatment exposure and discontinuation in the PALLAS trial: PALbociclib CoLlaborative Adjuvant Study of palbociclib with adjuvant endocrine therapy for HR+/HER2-early breast cancer
Mayer, Erica L.
Fesl, Christian
Dueck, Amylou
Gnant, Michael
DeMichele, Angela
CANCER RESEARCH, 2021, 81 (04)
[5] Adherence with adjuvant endocrine therapy with or without Palbociclib in the PALLAS trial
Shinn, Eileen
Zahrieh, David
DeMichele, Angela
Zdenkowski, Nick
Lemieux, Julie
Mao, Jun
Bjelic-Radisic, Vesna
Naughton, Michelle
Pfeiler, Georg
Gelmon, Karen
Mayer, Ingrid
Egle, Daniel
Zoppoli, Gabriele
Traina, Tiffany
Jimenez, Miguel Martin
Novoa, Silvia Antolin
Haddad, Tufia
Chan, Arlene
Ring, Alistair Edward
Wolff, Antonio
Lorenzo, Jose JuanPonce
Sabanathan, Dhanusha
Burstein, Hal
Nowecki, Zbigniew Ireneusz
Pristauz-Telsnigg, Gunda
Brufsky, Adam
Bellet-Ezquerra, Meritxell
Foukakis, Theodoros
Novik, Yelena
Rubovszky, Gabor
Muehlbacher, Karoline
Metzger, Otto
Goulioti, Theodora
Law, Ernest
Partridge, Ann
Carey, Lisa
Zoroufy, Alex
Hlauschek, Dominik
Fesl, Christian
Mayer, Erica
Gnant, Michael
CANCER RESEARCH, 2022, 82 (04)
[6] Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR+/HER2-early breast cancer
Slamon, Dennis J.
Fasching, Peter A.
Hurvitz, Sara
Chia, Stephen
Crown, John
Martin, Miguel
Barrios, Carlos H.
Bardia, Aditya
Im, Seock-Ah
Yardley, Denise A.
Untch, Michael
Huang, Chiun-Sheng
Stroyakovskiy, Daniil
Xu, Binghe
Moroose, Rebecca L.
Loi, Sherene
Visco, Frances
Bee-Munteanu, Valerie
Afenjar, Karen
Fresco, Rodrigo
Taran, Tetiana
Chakravartty, Arunava
Zarate, Juan Pablo
Lteif, Agnes
Hortobagyi, Gabriel N.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
[7] Adaptlate -a randomized, controlled, open-label, phase-iii trial on adjuvant dynamic marker - adjusted personalized therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (clinical or genomic) high risk, hr+/her2-early breast cancer
Gluz, Oleg
Degenhardt, Tom
Marschner, Norbert
Christgen, Matthias
Kreipe, Hans Heinrich
Nitz, Ulrike
Kates, Ronald
Schinkoethe, Timo
Graeser, Monika
Wurstlein, Rachel
Kuemmel, Sherko
Harbeck, Nadia
CANCER RESEARCH, 2021, 81 (04)
[8] MonarchE: A randomized, open-label, phase 3 study of abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone in patients with high risk, node positive, early stage, HR+, HER2-breast cancer
Rastogi, Priya
Toi, Masakazu
Harbeck, Nadia
Bourayou, Nawel
Frenzel, Martin
Johnston, Stephen
CANCER RESEARCH, 2018, 78 (04)
[9] Quality of life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05)
Naughton, Michelle Joy
Zahrieh, David
Gnant, Michael
Zdenkowski, Nicholas
Lemieux, Julie
Mao, Jun J.
Bjelic-Radisic, Vesna
Shinn, Eileen
Balic, Marija
Thomssen, Christoph
Neisel, Jane
Ruiz-Echarri, Manuel
Loibl, Sibylle
Isaacs, Claudine
Cameron, David
Carrasco, Fernando Manuel Henao
Goetz, Matthew
Wette, Viktor
Werutsky, Gustavo
Rugo, Hope
Vetter, Marcus
Tseng, Ling-Ming
Miller, Kathy
Fitzal, Florian
Gil, Juan Miguel Gil
Park, Haeseong
Linderholm, Barbro
Bajetta, Emilio
Dayao, Zoneddy
Prat, Aleix
Ehrhardt, Karin
Metzger, Otto
Arahmani, Amal
Law, Ernest
Partridge, Ann
Carey, Lisa
Zoroufy, Alex
Dueck, Amylou
Hlauschek, Dominik
DeMichele, Angela
Mayer, Erica
CANCER RESEARCH, 2022, 82 (04)
[10] ADAPTlate: A randomized, controlled, open-label, phase III trial on adjuvant dynamic marker-Adjusted personalized therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (clinical or genomic) high-risk, HR+/HER2-early breast cancer.
Gluz, Oleg
Scheffen, Iris
Degenhardt, Tom
Marschner, Norbert Walter
Christgen, Matthias
Kreipe, Hans Heinrich
Nitz, Ulrike
Kates, Ronald E.
Schinkoethe, Timo
Graeser, Monika Karla
Wuerstlein, Rachel
Kuemmel, Sherko
Bauer, Lelia
Schem, Christian
Fehm, Tanja N.
Neubauer, Hans
Harbeck, Nadia
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

← 1 2 3 4 5 →